2. Signaling Pathways
  3. Cytoskeleton
  4. Claudin
  5. CLDN18 Isoform

CLDN18

 

CLDN18 Related Products (6):

Cat. No. Product Name Effect Purity
  • HY-P991564
    Arcotatug
    		Inhibitor
    Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs.
  • HY-P991681
    Emaretamig
    		Inhibitor
    Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research.
  • HY-P991140
    Garetatug
    		Ligand
    Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity.
  • HY-P991163
    Tixentamig
    		Inhibitor ≥99.0%
    Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers.
  • HY-P992316
    ATG-022 Antibody
    		Modulator
    ATG-022 Antibody is a humanized monoclonal antibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer.
  • HY-P992412
    MIL93
    		Inhibitor
    MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001).